Arca
Skip to content
Tools
Tools

LIPF: Gastric triacylglycerol lipase

Catalyzes the hydrolysis of triacylglycerols to yield free fatty acids, diacylglycerol, monoacylglycerol, and glycerol.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on LIPF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Orlistat

Phase 30

    Phase 21

    • Cetilistat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      OrlistatApprovedCheplapharmSmall moleculeInhibitorGastric lipase inhibitor10
      CetilistatPhase 2AlizymeSmall moleculeInhibitorGastric lipase inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical TrialOrlistatNot applicableRecruitingKhyber Medical University PeshawarAug 5, 2026
      Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical HyperplasiaOrlistatPhase 2Not yet recruitingPeking University People's HospitalJul 20, 2026
      Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCTOrlistatNot applicableNot yet recruitingXueMei GuoJan 8, 2026
      RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.OrlistatPhase 4Not yet recruitingThe Fourth Affiliated Hospital of Zhejiang University School of MedicineDec 24, 2025
      Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Orlistat—Active, not recruitingOhio State UniversitySep 23, 2025
      A Trial With EMP16 in Preparation for Late Phase StudiesOrlistatPhase 2Not yet recruitingEmpros Pharma ABMay 28, 2025
      Weight Loss Management in Endometrial Cancer SurvivorsOrlistat—Active, not recruitingUniversity of Kansas Medical CenterMar 14, 2025
      Orlistat Overcoming Third-generation EGFR-TKI ResistanceOrlistatPhase 2Not yet recruitingPing PengFeb 11, 2025

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Obesity disorder
      0.58
      Type 2 diabetes mellitus
      0.47
      Inherited lipid metabolism disorder
      0.37
      Type 1 diabetes mellitus
      0.28
      Proptosis
      0.17
      Progressive visual loss
      0.16
      Liver disorder
      0.10
      Reading and spelling ability
      0.10
      Refractive error
      0.09

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1796, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P07098, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.